279 related articles for article (PubMed ID: 27502866)
1. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD
Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866
[TBL] [Abstract][Full Text] [Related]
2. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
Harskamp RE; Clare RM; Ambrosio G; Held C; Lokhnygina Y; Moliterno DJ; White HD; Aylward PE; Armstrong PW; Mahaffey KW; Harrington RA; Van de Werf F; Wallentin L; Strony J; Tricoci P
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):155-163. PubMed ID: 26895973
[TBL] [Abstract][Full Text] [Related]
3. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
Whellan DJ; Tricoci P; Chen E; Huang Z; Leibowitz D; Vranckx P; Marhefka GD; Held C; Nicolau JC; Storey RF; Ruzyllo W; Huber K; Sinnaeve P; Weiss AT; Dery JP; Moliterno DJ; Van de Werf F; Aylward PE; White HD; Armstrong PW; Wallentin L; Strony J; Harrington RA; Mahaffey KW
J Am Coll Cardiol; 2014 Mar; 63(11):1048-57. PubMed ID: 24211500
[TBL] [Abstract][Full Text] [Related]
4. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
Held C; Tricoci P; Huang Z; Van de Werf F; White HD; Armstrong PW; Ambrosio G; Aylward PE; Moliterno DJ; Wallentin L; Chen E; Erkan A; Jiang L; Strony J; Harrington RA; Mahaffey KW
Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):246-56. PubMed ID: 24627331
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
[TBL] [Abstract][Full Text] [Related]
6. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.
White HD; Huang Z; Tricoci P; Van de Werf F; Wallentin L; Lokhnygina Y; Moliterno DJ; Aylward PE; Mahaffey KW; Armstrong PW
J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25012288
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
[TBL] [Abstract][Full Text] [Related]
8. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery.
van Diepen S; Tricoci P; Podder M; Westerhout CM; Aylward PE; Held C; Van de Werf F; Strony J; Wallentin L; Moliterno DJ; White HD; Mahaffey KW; Harrington RA; Armstrong PW
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26672080
[TBL] [Abstract][Full Text] [Related]
10. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
Jones WS; Tricoci P; Huang Z; Moliterno DJ; Harrington RA; Sinnaeve PR; Strony J; Van de Werf F; White HD; Held C; Armstrong PW; Aylward PE; Chen E; Patel MR; Mahaffey KW
Am Heart J; 2014 Oct; 168(4):588-96. PubMed ID: 25262270
[TBL] [Abstract][Full Text] [Related]
11. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
[TBL] [Abstract][Full Text] [Related]
12. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Tricoci P; Lokhnygina Y; Huang Z; Van de Werf F; Cornel JH; Chen E; Wallentin L; Held C; Aylward PE; Moliterno DJ; Jennings LK; White HD; Armstrong PW; Harrington RA; Strony J; Mahaffey KW
Am Heart J; 2014 Dec; 168(6):869-77.e1. PubMed ID: 25458650
[TBL] [Abstract][Full Text] [Related]
13. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
Déry JP; Mahaffey KW; Tricoci P; White HD; Podder M; Westerhout CM; Moliterno DJ; Harrington RA; Chen E; Strony J; Van de Werf F; Ziada KM; Held C; Aylward PE; Armstrong PW; Rao SV
Catheter Cardiovasc Interv; 2016 Aug; 88(2):163-73. PubMed ID: 26698636
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
[TBL] [Abstract][Full Text] [Related]
15. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
Mahaffey KW; Huang Z; Wallentin L; Storey RF; Jennings LK; Tricoci P; White HD; Armstrong PW; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Leonardi S; Rorick T; Held C; Strony J; Harrington RA
Am J Cardiol; 2014 Mar; 113(6):936-44. PubMed ID: 24444781
[TBL] [Abstract][Full Text] [Related]
16. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW
Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022
[TBL] [Abstract][Full Text] [Related]
17. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
Valgimigli M; Tricoci P; Huang Z; Aylward PE; Armstrong PW; Van de Werf F; Leonardi S; White HD; Widimsky P; Harrington RA; Cequier A; Chen E; Lokhnygina Y; Wallentin L; Strony J; Mahaffey KW; Moliterno DJ
Am J Cardiol; 2014 Sep; 114(5):665-73. PubMed ID: 25129064
[TBL] [Abstract][Full Text] [Related]
18. The FDA report on vorapaxar in the elderly: A convoluted dilemma.
Serebruany VL; Fortmann SD
Int J Cardiol; 2015 Dec; 201():601-3. PubMed ID: 26340124
[TBL] [Abstract][Full Text] [Related]
19. Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
[TBL] [Abstract][Full Text] [Related]
20. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
Cavender MA; Scirica BM; Bonaca MP; Angiolillo DJ; Dalby AJ; Dellborg M; Morais J; Murphy SA; Ophuis TO; Tendera M; Braunwald E; Morrow DA
Circulation; 2015 Mar; 131(12):1047-53. PubMed ID: 25681464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
